ClinicalTrials.gg
Active, not recruitingNCT05023980BRUIN-CLL-313Updated Sep 25, 2026Results posted

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 3 interventional study of Pirtobrutinib and Bendamustine in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 108 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment

Updated Sep 25, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 23
282 · median 87
Started
2021
with 3 others
Phase 3
6 of 23
3 open now
Primary completion
2025-07
later than 1 of 18 live
Registered
5th of 23
by date
Lead sponsor
6 of 23
Loxo Oncology, Inc.

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, reaches primary completion later than 1 of the 18 other live ones, and was the 5th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • BTKi
  • BTK Inhibitor
  • Hematologic Disease
  • Lymphoma, non-Hodgkin's
  • Lymphoma, B-cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CLL/SLL requiring therapy, per iwCLL 2018 criteria
  • (ECOG) Performance Status 0-2
  • Adequate organ function
  • greater than or equal to (≥)75 x 10⁹/liter (L) (≥50 × 10⁹/L for patients with evidence of bone marrow infiltrate), ≥8 grams/deciliter (g/dL), and ≥0.75 x 10⁹/L
  • Kidney function: Estimated ≥40 milliliters per minute (mL/min)

Exclusion criteria

Exclusion Criteria:

  • Known or suspected Richter's transformation at any time preceding enrollment
  • Prior systemic therapy for CLL/SLL
  • Presence of 17p deletion
  • Central nervous system (CNS) involvement
  • Active uncontrolled auto-immune cytopenia (e.g., hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP])
  • Significant cardiovascular disease
  • Active or
  • Active cytomegalovirus (CMV) infection
  • Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Known (HIV) infection, regardless of cluster of differentiation 4 (CD4) count
  • Concurrent use of agent or anticancer therapy except hormonal therapy
  • Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist
  • Vaccination with a within 28 days prior to randomization
  • Patients with the following :

    • Known hypersensitivity, including anaphylaxis, to any component or of pirtobrutinib or bendamustine
    • Prior significant hypersensitivity to rituximab
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    Arm A - Pirtobrutinib

    Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.

    Drug: Pirtobrutinib

  • Active comparator
    Arm B - Bendamustine Plus Rituximab

    Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).

    Drug: Bendamustine · Drug: Rituximab

Interventions

  • Oral

    Also known as: LOXO-305, LY3527727

  • IV

    Also known as: Treanda, Treakisym, Ribomustin, Levact

  • IV

    Also known as: Rituxan, MabThera, Truxima, Riabni, Ruxience

06

What researchers measure

Primary outcomes

  1. Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)

    PFS, as assessed by IRC, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.

    Time frame: From randomization until documented disease progression or death (up to 40 months)

Secondary outcomes

  1. Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator

    PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.

    Time frame: From randomization until documented disease progression or death (up to 40 months)

  2. To Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)

    Assessments of effectiveness include OS, assessed by investigator

    Time frame: Up to approximately 5 years

  3. Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator

    TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first.

    Time frame: From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)

  4. Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC

    ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.

    Time frame: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)

  5. Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator

    ORR, as assessed by investigator, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.

    Time frame: From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)

  6. Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC

    DoR, as assessed by IRC, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.

    Time frame: From first documented response until the first documented disease progression or death (up to 35 months)

  7. Arm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator

    DoR, as assessed by investigator, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.

    Time frame: From first documented response until the first documented disease progression or death (up to 35 months)

  8. Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58

    A measure of CLL/SLL-related symptoms (CLL/SLL-related Symptoms score) was derived from 13 items: appetite loss, fatigue (3 items), pain, nausea, dyspnea, and insomnia from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), and night sweats, fever/chills, and fatigue (3 items) from selected items of the EORTC Item Library set 58 (IL-58). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing worse symptoms. TTW of CLL/SLL-related symptoms was defined as the time from randomization to the earliest date of the first sustained worsening in its score from baseline, meeting or exceeding the meaningful within-person change (MWPC) threshold of +5.12 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.

    Time frame: From randomization up to 37 months

  9. Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30

    Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.

    Time frame: From randomization up to 37 months

Other outcomes

  1. Arm A Compared to Arm B: Overall Survival, Assessed by Investigator

    Overall survival (OS) is defined as the time from randomization until death from any cause. A descriptive analysis of OS was pre-specified based on the primary endpoint data cutoff.

    Time frame: From randomization until death from any cause (up to 41 months)

07

Results

Posted Sep 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Started141141
Received at least one dose of study drug (including a partial dose)140132
Arm b participants who crossed over to receive pirtobrutinib018
Completed00
Not completed141141
Withdrew: On study130108
Withdrew: Death310
Withdrew: Lost to follow-up02
Withdrew: Withdrawal of consent519
Withdrew: Sponsor decision20
Withdrew: Participant did not agree to full active follow-up visits11
Withdrew: Participant denied doing more than one computerized axial tomography test per year01

Outcome measures

PrimaryArm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)

PFS, as assessed by IRC, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.

Time frame:
From randomization until documented disease progression or death (up to 40 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)NA (NA to NA)33.54 (32.72 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = <.0001 (The 2-sided p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.199 · 95% CI 0.107 to 0.367The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryArm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator

PFS, as assessed by investigator, is defined as the time from randomization until documented disease progression as per iwCLL (International Workshop on Chronic Lymphocytic Leukemia) 2018 criteria, or death from any cause, whichever occurs first.

Time frame:
From randomization until documented disease progression or death (up to 40 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Investigator
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by InvestigatorNA (35.19 to NA)NA (33.38 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = <.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.186 · 95% CI 0.093 to 0.371The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryTo Evaluate the Effectiveness of Arm A Compared to Arm B: Overall Survival (OS)

Assessments of effectiveness include OS, assessed by investigator

Time frame:
Up to approximately 5 years

Results for this outcome have not been posted.

SecondaryArm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator

TTNT is defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) including the first dose date of pirtobrutinib for Arm B participants who crossed over to receive pirtobrutinib if applicable or death due to any cause, whichever occurs first.

Time frame:
From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by Investigator
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Time to Next Treatment (TTNT), Assessed by InvestigatorNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = <.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.136 · 95% CI 0.056 to 0.332The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryArm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC

ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.

Time frame:
From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
Reported as:
Number · Percentage of participants
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC
Percentage of participantsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC94.3 (89.13 to 97.52)80.9 (73.38 to 86.99)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Cochran-Mantel-Haenszel · p = 0.0006
SecondaryArm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator

ORR, as assessed by investigator, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.

Time frame:
From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
Reported as:
Number · Percentage of participants
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator
Percentage of participantsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by Investigator94.3 (89.13 to 97.52)82.3 (74.95 to 88.18)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Cochran-Mantel-Haenszel · p = 0.0017
SecondaryArm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC

DoR, as assessed by IRC, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.

Time frame:
From first documented response until the first documented disease progression or death (up to 35 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRC
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by IRCNA (NA to NA)29.86 (28.32 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = <.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.178 · 95% CI 0.089 to 0.356The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryArm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator

DoR, as assessed by investigator, is defined as the time from the date of the first documented response (CR, CRi, nPR, or PR) until the first date of the documentation of disease progression as per iwCLL 2018 criteria, or the date of death from any cause, whichever occurs first.

Time frame:
From first documented response until the first documented disease progression or death (up to 35 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by Investigator
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Duration of Response (DOR), Assessed by InvestigatorNA (31.21 to NA)NA (29.86 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = <.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.193 · 95% CI 0.089 to 0.418The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryArm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58

A measure of CLL/SLL-related symptoms (CLL/SLL-related Symptoms score) was derived from 13 items: appetite loss, fatigue (3 items), pain, nausea, dyspnea, and insomnia from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), and night sweats, fever/chills, and fatigue (3 items) from selected items of the EORTC Item Library set 58 (IL-58). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing worse symptoms. TTW of CLL/SLL-related symptoms was defined as the time from randomization to the earliest date of the first sustained worsening in its score from baseline, meeting or exceeding the meaningful within-person change (MWPC) threshold of +5.12 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.

Time frame:
From randomization up to 37 months
Reported as:
Median · Months
Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = 0.011 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.501 · 95% CI 0.291 to 0.863The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryArm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30

Physical Functioning was assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Physical Function (PF) scale consisting of 5 items to measure the impact of the disease and its treatment on a participant's ability to perform everyday physical activities, calculated from responses to the five items, each scored on a 4 point scale (1 = not at all to 4 = very much). First, a raw score was calculated as mean of the item responses, then a linear transformation was applied to obtain standardized score ranging from 0 to 100, with higher score representing better functioning. TTW of PF was defined as the time from randomization to the earliest date of the first sustained worsening from baseline, with a decline in the meaningful within-person change (MWPC) threshold of -13.33 points or death from any cause. Sustained worsening required that the threshold be met at two consecutive assessment timepoints.

Time frame:
From randomization up to 37 months
Reported as:
Median · Months
Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30NA (NA to NA)NA (33.54 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = 0.091 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.578 · 95% CI 0.304 to 1.099The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
Other pre-specifiedArm A Compared to Arm B: Overall Survival, Assessed by Investigator

Overall survival (OS) is defined as the time from randomization until death from any cause. A descriptive analysis of OS was pre-specified based on the primary endpoint data cutoff.

Time frame:
From randomization until death from any cause (up to 41 months)
Reported as:
Median · Months
Arm A Compared to Arm B: Overall Survival, Assessed by Investigator
MonthsArm A - PirtobrutinibArm B - Bendamustine Plus Rituximab
Arm A Compared to Arm B: Overall Survival, Assessed by InvestigatorNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Bendamustine Plus Rituximab · Log Rank · p = 0.0261 (The 2-sided p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.257 · 95% CI 0.070 to 0.934The HR and 95% CI were estimated from a stratified Cox proportional hazards model.

Adverse events

Collected over From randomization up to 41 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Pirtobrutinib3/141 (2.1%)43/140 (30.7%)109/140 (77.9%)
Arm B - Bendamustine Plus Rituximab10/141 (7.1%)41/132 (31.1%)111/132 (84.1%)
Arm B - Crossover to Pirtobrutinib0/18 (0%)1/18 (5.6%)11/18 (61.1%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventArm A - PirtobrutinibArm B - Bendamustine Plus RituximabArm B - Crossover to Pirtobrutinib
Respiratory tract infectionInfections and infestations1/1400/1321/18
Febrile neutropeniaBlood and lymphatic system disorders2/1407/1320/18
PneumoniaInfections and infestations7/1404/1320/18
AnaemiaBlood and lymphatic system disorders3/1404/1320/18
Covid-19Infections and infestations2/1404/1320/18
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/831/850/16
Covid-19 pneumoniaInfections and infestations0/1403/1320/18
Infusion related reactionInjury, poisoning and procedural complications0/1403/1320/18
Tumour lysis syndromeMetabolism and nutrition disorders0/1403/1320/18
InfectionInfections and infestations0/1402/1320/18
Most frequent other events
Showing 10 of 49
Most frequent other events
EventArm A - PirtobrutinibArm B - Bendamustine Plus RituximabArm B - Crossover to Pirtobrutinib
NeutropeniaBlood and lymphatic system disorders17/14055/1320/18
NauseaGastrointestinal disorders3/14031/1320/18
Covid-19Infections and infestations29/1409/1320/18
PyrexiaGeneral disorders12/14025/1320/18
Upper respiratory tract infectionInfections and infestations25/14011/1321/18
AnaemiaBlood and lymphatic system disorders13/14021/1321/18
Infusion related reactionInjury, poisoning and procedural complications0/14018/1320/18
RashSkin and subcutaneous tissue disorders15/14018/1320/18
ThrombocytopeniaBlood and lymphatic system disorders11/14017/1320/18
ArthralgiaMusculoskeletal and connective tissue disorders17/1401/1320/18

Baseline characteristics

All randomized participants

Age, Categorical
Age, Categorical(Participants)Arm A - PirtobrutinibArm B - Bendamustine Plus RituximabTotal
<=18 years000
Between 18 and 65 years6857125
>=65 years7384157
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - PirtobrutinibArm B - Bendamustine Plus RituximabTotal
Female5851109
Male8390173
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A - PirtobrutinibArm B - Bendamustine Plus RituximabTotal
Hispanic or Latino111526
Not Hispanic or Latino126122248
Unknown or Not Reported448
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - PirtobrutinibArm B - Bendamustine Plus RituximabTotal
American Indian or Alaska Native000
Asian333164
Native Hawaiian or Other Pacific Islander112
Black or African American011
White104102206
More than one race235
Unknown or Not Reported134
08

Study locations

108 sites

Showing the first 100 of 108 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eyre TA, Hess LM, Masoudi E, Jen MH, Abhyankar S, Graham-Clarke PL, Bhandari NR, Maguire P, Winfree KB, Tracey M, Taipale KL, Davids MS. Efficacy of Pirtobrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Cancers (Basel). 2026 Feb 18;18(4):660. doi: 10.3390/cancers18040660. PubMed 41749915 ↗
  • Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026 Feb 20;44(6):466-475. doi: 10.1200/JCO-25-02380. Epub 2025 Dec 9. PubMed 41363773 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jul 2025, 45 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 27, 2021
StartActual
Sep 23, 2021
Primary completionActual
Jul 11, 2025
CompletionEst.
Oct 2027
Results first posted
Sep 25, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 25, 2026
Enrollment
309→282
Sep 25, 2026
Interventions
Arm changed Arm A (Pirtobrutinib)→Arm A - Pirtobrutinib; Arm B (BR)→Arm B - Bendamustine Plus Rituximab
Sep 25, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)Now Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)Time frame: Up to approximately 5 years → From randomization until documented disease progression or death (up to 40 months)
Sep 25, 2026
Documents
Secondary outcomes
5 edited, 5 added, 2 removed
What changed in the outcomes
  • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Progression-free survivalSurvival (PFS), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until documented disease progression or death (up to 40 months)
  • EditedTo evaluateEvaluate the effectivenessEffectiveness of Arm A comparedCompared to Arm B: Overall survivalSurvival (OS)Time frame: Up to approximately 5 years
  • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Time to next treatmentNext Treatment (TTNT), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
  • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Percentage of Participants With Overall response rateResponse (ORR), Assessed by IRCTime frame: Up to approximately 5 years → From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
  • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: DurationPercentage of Participants With Overall Response (DORORR), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
  • AddedArm A Compared to Arm B: Duration of Response (DOR), Assessed by IRCTime frame: From first documented response until the first documented disease progression or death (up to 35 months)
  • AddedArm A Compared to Arm B: Duration of Response (DOR), Assessed by InvestigatorTime frame: From first documented response until the first documented disease progression or death (up to 35 months)
  • AddedArm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58Time frame: From randomization up to 37 months
  • AddedArm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30Time frame: From randomization up to 37 months
  • RemovedTo evaluate the effectiveness of Arm A compared to Arm B in patient-reported disease-related symptomsTime frame: Up to approximately 5 years
  • RemovedTo evaluate the effectiveness of Arm A compared to Arm B in patient-reported physical functioningTime frame: Up to approximately 5 years
  • Addedother outcomeArm A Compared to Arm B: Overall Survival, Assessed by InvestigatorTime frame: From randomization until death from any cause (up to 41 months)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Results posted
    Enrollment 309→282
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)Now Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)Time frame: Up to approximately 5 years → From randomization until documented disease progression or death (up to 40 months)
    Secondary outcomes 5 edited, 5 added, 2 removed
    What changed in the outcomes
    • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Progression-free survivalSurvival (PFS), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until documented disease progression or death (up to 40 months)
    • EditedTo evaluateEvaluate the effectivenessEffectiveness of Arm A comparedCompared to Arm B: Overall survivalSurvival (OS)Time frame: Up to approximately 5 years
    • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Time to next treatmentNext Treatment (TTNT), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until initiation of the subsequent anticancer therapy or death (up to 41 months)
    • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: Percentage of Participants With Overall response rateResponse (ORR), Assessed by IRCTime frame: Up to approximately 5 years → From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
    • EditedTo evaluate the effectiveness of Arm A comparedCompared to Arm B: DurationPercentage of Participants With Overall Response (DORORR), Assessed by InvestigatorTime frame: Up to approximately 5 years → From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)
    • AddedArm A Compared to Arm B: Duration of Response (DOR), Assessed by IRCTime frame: From first documented response until the first documented disease progression or death (up to 35 months)
    • AddedArm A Compared to Arm B: Duration of Response (DOR), Assessed by InvestigatorTime frame: From first documented response until the first documented disease progression or death (up to 35 months)
    • AddedArm A Compared to Arm B: Time to Worsening (TTW) of CLL/SLL-related Symptoms as Measured by the EORTC QLQ-C30 and IL-58Time frame: From randomization up to 37 months
    • AddedArm A Compared to Arm B: Time to Worsening (TTW) of Physical Functioning as Measured by the Physical Function Domain of the EORTC-QLQ-C30Time frame: From randomization up to 37 months
    • RemovedTo evaluate the effectiveness of Arm A compared to Arm B in patient-reported disease-related symptomsTime frame: Up to approximately 5 years
    • RemovedTo evaluate the effectiveness of Arm A compared to Arm B in patient-reported physical functioningTime frame: Up to approximately 5 years
    • Addedother outcomeArm A Compared to Arm B: Overall Survival, Assessed by InvestigatorTime frame: From randomization until death from any cause (up to 41 months)
    Interventions Arm changed Arm A (Pirtobrutinib)→Arm A - Pirtobrutinib; Arm B (BR)→Arm B - Bendamustine Plus Rituximab
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05023980
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Sep 23, 2021
Primary completion
Jul 11, 2025
Completion
Oct 2027 (estimated)
Results posted
Sep 25, 2026
Last update
Sep 25, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion